Influenza virus shedding and symptoms: Dynamics and implications from a multi-season
household transmission study

Sinead E. Morris, PhD[1,2,*], Huong Q. Nguyen, PhD, MPH[3], Carlos G. Grijalva, MD, MPH[4], Kayla E. Hanson,
MPH[3], Yuwei Zhu, MD, MS[4], Jessica E. Biddle, MPH[1], Jennifer K. Meece, PhD[3], Natasha B. Halasa, MD,
MPH[4], James D. Chappell, MD, PhD[4], Alexandra M. Mellis, PhD[2], Carrie Reed, DSc, MPH[1], Matthew
Biggerstaff, ScD, MPH[1], Edward A. Belongia, MD[3], H. Keipp Talbot, MD, MPH[4], Melissa A. Rolfes, PhD,
MPH[1]

[1]Influenza Division, Centers for Disease Control and Prevention, Atlanta, GA, USA
[2]Goldbelt Professional Services, Chesapeake, VA, USA
[3]Marshfield Clinic Research Institute, Marshfield, WI, USA
[4]Vanderbilt University Medical Center, Nashville, TN, USA
12

*Corresponding author: Sinead Morris, run7@cdc.gov, Centers for Disease Control and Prevention, 1600
Clifton Rd NE, Atlanta, GA, 30033

Competing Interest Statement: H.Q.N receives research support unrelated to this work from CSL
Seqirus and GSK, and honorarium for participating in a consultancy group for Moderna outside the
submitted work. C.G.G received research support unrelated to this work from Merck. K.E.H, J.K.M, and
E.A.B receive research support unrelated to this work from CSL Seqirus. The authors have no competing
interests to declare.

Keywords: seasonal influenza; virus shedding; symptom severity; transmission dynamics; household
study

Abstract

Isolation of symptomatic infectious persons can reduce influenza transmission. However, virus shedding that occurs without symptoms will be unaffected by such measures. Identifying effective isolation strategies for influenza requires understanding the interplay between individual virus shedding and symptom presentation. From 2017–2020, we conducted a case-ascertained household transmission study using influenza real-time reverse transcription quantitative PCR (RT-qPCR) testing of nasal swabs and daily symptom diary reporting for up to 7 days after enrollment (≤14 days after index onset). We assumed real-time RT-qPCR cycle threshold (Ct) values were indicators of quantitative virus shedding and used symptom diaries to create a score that tracked influenza-like-illness (ILI) symptoms (fever, cough, or sore throat). We fit phenomenological nonlinear mixed-effects models stratified by age and vaccination status and estimated two quantities influencing isolation effectiveness: shedding before symptom onset and shedding that might occur once isolation ends. We considered different isolation end points (including 24 hours after fever resolution or 4 days after symptom onset) and assumptions about the infectiousness of Ct shedding trajectories. Of the 116 household contacts with ≥2 positive tests for longitudinal analyses, 105 (91%) experienced ≥1 ILI symptom. On average, children <5 years experienced greater peak shedding, longer durations of shedding, and elevated ILI symptom scores compared with other age groups. Most individuals (63/105) shed <10% of their total shed virus before symptom onset, and shedding after isolation varied substantially across individuals, isolation end points, and infectiousness assumptions. Our results can inform strategies to reduce transmission from symptomatic individuals infected with influenza.

Significance Statement

Individuals infected with influenza are encouraged to avoid contact with others for a period following symptom onset. This action should reduce the likelihood of onward transmission if infectious virus shedding is associated with symptom presentation. We modeled influenza virus shedding and symptom dynamics in participants of a multi-season household transmission study. On average, children <5 years shed more virus for longer durations and experienced elevated influenza-like-illness symptoms compared with older age groups. Most shedding took place after symptom onset, and estimated shedding that might remain after a period of avoiding contact with others depended on how the end of this period was defined. Our results can help inform strategies to reduce transmission from symptomatic individuals infected with influenza.

Introduction

Seasonal influenza causes substantial morbidity and mortality in the United States each year [1]. Measures to mitigate this burden include pharmaceutical interventions, such as vaccination, and nonpharmaceutical interventions, such as case isolation. The latter is designed to reduce exposure to virus shedding from symptomatic individuals, thereby reducing the potential for onward transmission. The Centers for Disease Control and Prevention (CDC) recommends symptomatic individuals stay at home and avoid contact with others until 24 hours after fever resolution, or for 4-5 days following symptom onset if they do not experience fever [2, 3]. However, transmission will be unaffected by such mitigation measures if it occurs in the absence of symptoms (for example, prior to symptom onset or

from asymptomatic individuals) or after the recommended duration has passed. Understanding how the
timing and progression of influenza symptoms relate to influenza virus shedding and transmission is
crucial to determining the potential impact of different strategies for reducing onward transmission
from symptomatic individuals [4, 5].

Studies of influenza transmission within households provide valuable information on the natural history
of infection [6]. Individual shedding and infection progression can be followed through routine PCR
testing of household members and recording of symptoms that arise [7, 8]. Such information can be
used to characterize patterns of virus shedding from asymptomatic and symptomatic individuals, and to
estimate household secondary attack rates and influenza vaccine effectiveness [9-13]. Individual-level
data can also be modeled to explore potential differences by age or vaccination status that may impact
the effectiveness of isolation [14-18]. Such insights have improved our understanding of effective
isolation measures for SARS-CoV-2 but are limited for influenza [19-21].

Here we modeled individual-level data from a household transmission study conducted across three
influenza seasons in the United States. We used cycle threshold (Ct) values obtained from real-time
reverse transcription quantitative PCR (RT-qPCR) testing of individual nasal swab specimens to infer
longitudinal virus shedding dynamics, and used symptom diaries to assess the relative timing and
progression of influenza-associated symptoms. We then identified differences in shedding and symptom
presentation by age and vaccination status, and estimated levels of pre-symptomatic shedding and
shedding that may remain once a mitigation measure, such as isolation, has ended. Our findings can
help inform effective strategies to reduce transmission from symptomatic individuals infected with
influenza.

Materials and Methods

Study

We conducted a case-ascertained household transmission study during the 2017-2018, 2018-2019 and
2019-2020 influenza seasons. Households were enrolled following the recruitment of index cases with
laboratory-confirmed influenza virus infection from clinics or testing sites in Wisconsin and Tennessee.
Households enrolled within seven days of the index illness onset date were eligible to participate and
followed for up to seven days after enrollment. Participants provided demographic information
including age and vaccination status at enrollment. Written informed consent was obtained for all
participants. Study protocols and procedures were reviewed by the Institutional Review Boards at the
Marshfield Clinic Research Institute and Vanderbilt University. CDC determined these activities were
conducted consistent with applicable federal law and CDC policy (see 45 C.F.R. part 46; 21 C.F.R. part
56). The study has been described in detail elsewhere [9, 22]; information relevant for the current
analysis is summarized below.

Virus shedding

Nasal swabs were collected daily from participants (either by study staff or self-/adult-collected) and
tested for influenza by real-time RT-qPCR. Testing was performed using the CDC Human Influenza Virus
Real-Time RT-PCR Diagnostic Panel and Influenza A/B Typing Kit at Marshfield Clinic Research Institute
or Vanderbilt University Medical Center. We inferred that real-time RT-qPCR Ct values were an indicator

of virus shedding and hereafter refer to samples with PCR positive Ct values as reflecting shed virus [23].
Since a positive Ct value does not necessarily reflect infectious virus, our Ct analyses relate to the total
viral genomic material an individual may shed, not solely that which is infectious. We explore different
assumptions about the relationship between Ct measurements and infectious virus in our analyses
below.

Ct values are inversely proportional to viral load such that higher Ct values reflect lower amounts of viral
material in a sample. Forty-five cycles were performed for each reaction and samples with Ct values <40
were deemed positive [24, 25]. Positive samples with values approaching 40 (e.g., values >36) were
repeated to ensure results were reproducible and all negative tests were assigned a value of 40. When
individuals had a self- and staff-collected test result on the same day, the Ct values were significantly
correlated (correlation = 0.6, p<0.0001) and so we used the result from the self-collected swab for
consistency. Although Ct values can vary between laboratories, we found no evidence of systematic
differences in Ct dynamics by testing site (Figure S1) and thus combined data from both sites in all
analyses.

Symptom scores

Symptom diaries identifying the presence of eight possible signs and symptoms associated with
influenza infection (fever, cough, sore throat, runny nose, nasal congestion, fatigue, shortness of breath,
and wheezing) were self-/adult-administered daily (Figure 1A). We translated these diaries into a
quantitative score, S_{ILI}, that measured the sum of influenza-like-illness (ILI) signs or symptoms reported
on each day as

$$S_{ILI} = 3 \text{ (fever)} + \text{sore throat} + \text{cough,}$$

where fever, sore throat, and cough equal 1 on days they were reported and 0 on days they were not
(Figure 1B). Fever was weighted more heavily as a proxy for increased clinical severity [26-28]. We also
defined an alternative score, S_{ANY}, that accounted for any sign or symptom assessed in the diaries. In this
score, shortness of breath and wheezing were more heavily weighted, in addition to fever, to include
greater lower respiratory tract involvement as a proxy for severity (Figure 1C) [26, 27, 29]. A value of 3
was assigned if at least one of fever, shortness of breath, or wheezing were reported; this value did not
increase if more than one was reported. Additional symptoms that were not included in the ILI
definition (nasal congestion, runny nose, and fatigue) were each weighted by 1/3, so that

$$S_{ANY} = 3 \text{ (fever or shortness of breath or wheezing)} + \text{sore throat} + \text{cough} + 1/3 \text{ (runny nose + nasal}$$
$$\text{congestion + fatigue).}$$

The weights for S_{ILI} and S_{ANY} were chosen to allow for back-translation of scores to the presence or
absence of fever, shortness of breath, or wheezing. For example, $S_{ILI} > 2$ can only occur if fever is
reported and $2 \geq S_{ILI} > 1$ can only occur if cough and sore throat are reported without fever. Similarly,
$S_{ANY} > 3$ can only occur if fever, shortness of breath, or wheezing are among the reported symptoms; this
would not be the case if runny nose, nasal congestion, or fatigue were weighted by 1 instead of 1/3.
Finally, we defined an unweighted score, S_{UNW}, that was simply the number of signs or symptoms
reported on any given day [10]. We compared this with S_{ILI} and S_{ANY} to assess the sensitivity of our results
to the choice of scoring weights.

155
Figure 1. Translation of symptom diaries to symptom scores. (A) Symptom diary reports from a child aged <5
years (left panel), a child aged 5-17 (middle) and an adult aged 50+ (right). ILI signs or symptoms (fever, cough,
sore throat) reported on a given day are highlighted in dark grey; all other reported symptoms are shown in light
grey. Diary reports from (A) are translated to ILI symptom scores, S_{ILI} (B), any symptom scores, S_{ANY} (C), and
unweighted symptom scores, S_{UNW} (D). In (B) and (C), colors indicate the presence of fever (B), or fever, wheezing,
or shortness of breath (C). Note these colors have different interpretations to those in (A). ILI stands for influenza-
like-illness.

Model

We assume viral shedding over time within an infected individual is proportional to a continuous
probability distribution, $f_v(t, a_v, b_v)$. Here, a_v and b_v are the distribution parameters, and t represents days
since ILI symptom onset (for analysis of individuals reporting ILI symptoms); days since any symptom
onset (for analysis of individuals reporting any symptoms); or days since first positive test (for analysis of
asymptomatic individuals). To allow variation in the magnitude and timing of shedding, we model the
amount of virus shed at time t, V(t), by

$$V(t) = h_v f_v(t - d_v, a_v, b_v),$$

where $h_v > 0$ is a magnitude scaling factor and d_v a shift in time. Similarly, we model the symptom score
(S_{ILI}, S_{ANY}, or S_{UNW}) of a symptomatic infected individual as

$$W(t) = h_w f_w(t - d_w, a_w, b_w),$$

where t represents days since ILI symptom onset (for S_{ILI}) or days since any symptom onset (for S_{ANY} and
S_{UNW}). We investigate three plausible distributions for f_v and f_w: lognormal, gamma, and Weibull
distributions [4, 11, 19, 30]. Since Ct values are bounded by 40 with higher values reflecting lower levels
of detected virus, we fit the Ct data with a transformed function, $\hat{V}(t) = 40 - V(t)$.

Model fitting and covariate analysis

Household contacts with at least two Ct values <40 were included in the modeling analysis. To mitigate
the impact of symptoms that were consistently reported due to causes other than influenza, we
discarded all data from individuals who reported symptoms on three or more days before testing
positive, when those days also coincided with a negative test. For analysis of symptomatic infection, we
included individuals whose first swab (positive or negative) was on or before symptom onset, and t = 0
anchored all trajectories at symptom onset. For analysis of asymptomatic infection, we could not use
time since symptom onset as a common anchor point. We therefore only included individuals with
'incident' infection (i.e., those with a recorded negative test before their first positive test). This allowed
us to use time since first positive test as a common anchor point that was at, or near, the onset of virus
shedding (Figure S2).

We fit $\hat{V}(t)$ and W(t) to the Ct and symptom score data, respectively, using a nonlinear mixed effects
framework [31, 32]. We assumed both variables were normally-distributed with constant error terms,
and ensured model residuals were normally-distributed using the Shapiro-Wilk test [33]. Each parameter
was assigned a fixed effect and an individual-level random effect; the latter captured variation between
participants. We assumed a, b and h were lognormally distributed to ensure positivity, and d was
normally distributed to allow positive or negative shifts in time. All parameters were assumed to be
independent, and we explored models that stratified one or more parameters by candidate covariates
for age group, vaccination status, virus type and season. The importance of each covariate-parameter
relationship was evaluated using ANOVA [31, 32].

The fit of each candidate model (lognormal, gamma, or Weibull) was compared using Akaike
Information Criterion (AIC), where lower AIC values reflect greater statistical support [34]. For the model
with lowest AIC, we simulated Ct and symptom trajectories for each individual using the fitted
parameter estimates. We then calculated key summary metrics, including the duration of shedding (or
duration of symptoms), the timing of peak shedding (or timing of peak symptom scores), and the area
under each curve. We tested for associations between these summary metrics and each candidate
covariate (listed above) using the non-parametric Kruskal-Wallis test and controlled the false-discovery
rate using the Benjamini-Hochberg correction. Further details on summary metric calculations are
provided in the Supplementary Information.

Due to sample size, we did not perform additional stratifications by multiple covariates when testing for
associations with the summary metrics described above. Instead, to distinguish covariates with the
greatest independent influence on trajectory dynamics from those acting primarily through collinearity
with other covariates, we performed hierarchical partitioning [35, 36]. Hierarchical partitioning provides
a systematic way to assess the independent influence of a particular covariate on a dependent variable,
after accounting for the effects of other covariates (additional details are provided in the Supplementary
Information). Statistical significance was assessed by comparing results to those obtained through 250
random permutations of the covariates.

Implications for isolation impact

We estimated the extent of shedding that would occur before and after a period of isolation by first
calculating the proportion of total shedding that had occurred up to any given day, t, as $F_v(t)$, where F_v is
the cumulative distribution of the best-fitting model for viral shedding, f_v. The proportion of shedding
that would have occurred prior to symptom onset and isolation (i.e., pre-symptomatic shedding) is $F_v(0)$,
and the proportion of shedding that would still occur if isolation ended on day t_I is $1 - F_v(t_I)$. These
estimates account for the magnitude of shedding, in addition to the duration, and are thus more
informative than estimates of shedding duration alone.

The value of t_I represents the duration of isolation and was assigned for each individual to align with
CDC recommendations for staying at home: t_I was set to 24 hours after fever resolution for those who
experienced fever, and after 4 (or 5) days post symptom onset for those who did not experience fever
[2, 3]. The 'back translation' property of S_{ILI} was used to identify individuals who experienced fever (i.e.,
attained $S_{ILI} >2$) and to determine the time of fever resolution (i.e., when the fitted S_{ILI} trajectory first
decreased below 2 after attaining its peak). Note that the fitted S_{ILI} trajectories are a continuous
representation of a discrete scoring system and so although fever is assigned a value of 3 in S_{ILI}, anything
greater than 2 (i.e. anything above the score assigned for cough + sore throat) is interpreted as possible
fever for the purpose of this analysis. In general, $S_{ILI} >2$ was a faithful indicator of those who experienced
fever (Supplementary Information).

Given that Ct values reflect total virus genomic material in a specimen rather than infectious shed virus
(i.e., virus with onward transmission potential) we also sought to translate our estimates of viral
shedding remaining following the end of isolation to estimates of infectious shedding, or transmission
potential, remaining. First, we defined several candidate functions, $g_v(t)$, to describe the proportion of
Ct-measured virus that is infectious at any given time. These included (i) a worst-case scenario in which

100% of Ct-measured virus is infectious for the entire duration of shedding; (ii) a best-case scenario in
which 100% of Ct-measured virus is infectious until 4 days post symptom onset, and then 0% for the
remainder; and (iii) an intermediate scenario in which the infectious percentage of Ct-measured virus
decreases linearly from 0 to 7 days following symptom onset [10, 30, 37, 38]. These functions were
designed for illustrative purposes and are not an exhaustive list of possible infectious virus dynamics.
We then estimated the percentage of transmission potential remaining at time t_I as $(1 - G_f(t_I)) \times 100\%$,
where $G_f(t)$ is the cumulative distribution of $g_v(t) \times f_v(t)$. Assuming secondary infections caused by an
infectious individual are distributed in proportion to their infectious shedding distribution, the number
of secondary infections generated following the end of isolation can be approximated as $R_t \times (1 - G_f(t_I))$,
where R_t is the effective reproduction number.

Model fitting and parameter estimation were conducted using Monolix 2021R2 and the
`lixoftConnectors` and `Rsmlx` packages in R 4.0.3 (Table S1) [39-42]. Downstream analyses and
plotting were conducted with the `hier.part`, `tidyverse`, `here`, `patchwork`, `ggpubr` and
`scico` packages [43-48]. Further methodological details are provided in the Supplementary
Information.

Results

We identified 116 household contacts with PCR-detectable influenza virus infection and at least two Ct
values <40 (Figure S2). Of these, 108 (93%) reported at least one symptom and 105 (91%) reported at
least one ILI symptom (fever, cough, or sore throat) during study follow-up (Table S2). Most infections
were caused by influenza A viruses (86/116; 74%), and 48 (41%) individuals were vaccinated with the
current season's influenza vaccine. Additional characteristics partitioned by age and vaccination status
or influenza-like-illness (ILI) symptoms are provided in Table S3.

For individuals experiencing at least one ILI symptom (N = 105), a Weibull distribution with shape
parameter (a) and magnitude parameter (h) modified by age provided the best-fit to the Ct data,
whereas a Weibull distribution with scale parameter (b) modified by age and magnitude modified by
vaccination status provided the best-fit to the S_{ILI} scores (Table S4, Figures S3-S5). Results were similar
when fitting to the Ct and S_{ANY} (or S_{UNW}) observations from those who reported any symptom (N = 108;
Table S5, Figures S5-S8). These findings suggest viral shedding dynamics differ by age, and symptom
score dynamics differ by age and vaccination status.

To investigate further, we tested whether age or vaccination status were associated with any trajectory
summary metrics. First, we found that young children (aged <5 years) shed significantly more total virus
($p < 0.0001$), had higher peaks in shedding ($p < 0.0001$), and had longer durations of shedding ($p <
0.0001$) relative to other age groups (Figure 2, Figure S9). Children aged <5 years also experienced higher
peaks in S_{ILI} than adults aged ≥50 years and shorter durations of S_{ILI} than adults ≥18 years (Figure S10, p
< 0.01). Conversely, there were no differences in peak symptom score by age when using S_{ANY} or S_{UNW}
(Figures S11-12). This was likely driven by the contribution of wheezing and shortness of breath to S_{ANY}
and S_{UNW}: older individuals, who were less likely to experience fever (Figure S10), were still assigned
higher symptom scores if they reported these additional symptoms (Figure S11). Thus, the S_{ANY} or S_{UNW}
scores may be more sensitive to symptom progression in older individuals.

285
Figure 2. Children aged <5 years shed more virus than other age groups. Associations between age group and
viral shedding summary metrics: (A) day of shedding clearance relative to ILI onset; (B) day of shedding onset
relative to ILI onset; (C) day of peak shedding relative to ILI onset; (D) duration of shedding in days; (E) Peak value
of shedding attained (transformed as 40 – Ct); and (F) total virus shed, as measured by the area under the fitted
shedding curve. ILI represents influenza-like-illness and AUC represents the area under the curve.*p <0.05, **p
<0.01, ***p <0.001, ****p <0.0001.

There were no significant associations between vaccination status and the viral shedding metrics (Figure
S13). This is unlikely to be confounded by age as the hierarchical partitioning analysis also found no
independent effect of vaccination status on the shedding summary metrics (Figure S14). In contrast,
vaccinated individuals experienced lower total S_{ILI} scores (p = 0.02) than unvaccinated individuals (Figure
3). Hierarchical partitioning confirmed that this observation was unlikely to be confounded by age
(Figure S14). Results were similar with S_{UNW}, although vaccinated individuals also experienced shorter
durations in S_{UNW} symptom scores (p <0.01) (Figure S15). Conversely, we found no systematic
relationship between the summary metrics and vaccination status with S_{ANY} (Figure S16).

301
Figure 3. Vaccinated individuals experience lower S_{ILI} **scores.** Associations between vaccination status and S_{ILI}
summary metrics: (A) time of peak S_{ILI} score relative to days since ILI onset; (B) duration of S_{ILI} score in days; (C)
peak S_{ILI} score attained; and (D) total S_{ILI} score, as measured by the area under the fitted S_{ILI} symptom curve. ILI
represents influenza-like-illness and AUC represents the area under the fitted symptom score curve. *p <0.05, **p
<0.01, ***p <0.001, ****p <0.0001.

Among the other covariates tested (virus type and season), we found an association between season
and the time of shedding: infections from 2017-2018 experienced later peaks in shedding (p <0.01) than
infections from 2018-2019 and 2019-2020 (Figure S17A). However, the hierarchical partitioning analysis
suggested this association may be confounded by age (Figure S14), since children <5 were not
represented in the 2017-18 data (Figure S1) and may experience earlier peaks in shedding (Figure 2). We
also did not detect any associations between shedding among individuals who reported higher ILI scores
(peak S_{ILI} >2) and those who reported lower scores (peak S_{ILI} ≤2) (Figure S17B).

Finally, we fit Ct data from 71 individuals with incident infection to compare shedding dynamics during
asymptomatic and symptomatic infection (Figures S2 and S18). Asymptomatic individuals experienced
substantially shorter durations of shedding than symptomatic individuals, in addition to lower peak and
total shedding levels (Figure S19). We did not include additional covariates or formally test these results
due to the sample size (8 asymptomatic infections and 63 symptomatic infections).

Implications for isolation impact

Any shedding that occurs prior to symptom onset ('pre-symptomatic shedding') will reduce the
effectiveness of isolation measures. In this study, we estimated that most individuals (60%; 63/105)
shed less than 10% of their total virus before the onset of an ILI symptom, although 15% (16/105) shed
more than 50% before onset (Figure 4A). Individuals in the latter group had no characteristic in common
with respect to age, vaccination status, type of infecting virus, or season of infection (Table S6). Across
all individuals there was a nonsignificant reduction in average pre-symptomatic shedding among adults
≥18 years compared to children <18 years (p = 0.2; Figure 4B), and no relationship with vaccination
status (Figure 4C).

330
Figure 4. Pre-symptomatic shedding is heterogeneous. (A) Distribution of pre-symptomatic shedding across all
individuals with ILI symptoms (N = 105). (B) Association between pre-symptomatic shedding and age group. (C)
Association between pre-symptomatic shedding and vaccination status. Pre-symptomatic shedding was estimated
as the percentage of total virus shedding that occurred prior to ILI symptom onset. ILI stands for influenza-like-
illness. *p <0.05, **p <0.01, ***p <0.001, ****p <0.0001.

In addition to pre-symptomatic shedding, shedding may also persist after isolation has ended. Current
recommendations advise symptomatic individuals infected with influenza viruses to stay at home and
avoid contact with others until 24 hours after fever resolution, or 4-5 days following symptom onset if
they do not experience fever [2, 3]. We henceforth refer to the former as a 'fever-based' strategy and
the latter as a 'duration-based' strategy. For those following the fever-based strategy (i.e., those who
experienced fever), we calculated the percentage of shedding remaining one day post fever resolution
(Figures 5A-B). For those who did not experience fever and instead followed the duration-based
strategy, we calculated the percentage of shedding remaining after four days post ILI symptom onset
(i.e., on day five post ILI symptom onset; Figure 5C). We considered shedding remaining after five days
post ILI symptom onset in sensitivity analyses (Figure S20). We then combined estimates across all
individuals to understand post-isolation shedding distributions at the population-level, if isolation
practices aligned with current recommendations for staying at home. In this study, the median
percentage of shedding remaining after isolation was 1-29% across age and vaccination groups, and
there was substantial inter-individual variation in shedding remaining and in isolation duration (Figures
5D-E). Notably, adults ≥ 65 years were less likely to experience fever and thus more likely to isolate for a
fixed duration of four days. We also identified eight individuals with fever would have isolated for over
six days. If all symptomatic participants instead followed the four-day duration-based strategy (i.e.,
everyone isolated for four days following ILI symptom onset), average estimates of shedding remaining
were equal to, or lower than, the combination of fever-based and duration-based strategies, and inter-
individual variation was greatly reduced (Figure 5F).

356
Figure 5. Duration-based isolation strategies are effective in reducing shedding remaining after isolation from
symptomatic individuals. (A-B) Example ILI symptom (A) and shedding remaining (B) trajectories from a child aged
5-17 years following a fever-based isolation strategy. The dashed vertical line represents the time of fever
resolution, and the solid vertical line represents the end of recommended isolation. (C) Corresponding shedding
remaining trajectory for the same child following a duration-based isolation strategy. (D-E) Estimates of shedding
remaining (D) and duration of isolation in days (E) assuming isolation practices align with current
recommendations for staying at home (i.e., a mixture of fever-based and duration-based strategies). (F) Estimates
of shedding remaining assuming all individuals follow a four day duration-based isolation strategy, including those
who experience fever. Estimates in (E, F) are stratified by age and vaccination status. Points represent the median
within each stratification and error bars are the 90th percentiles.

368
Figure 6. Framework for translating viral shedding to estimates of onward transmission potential. (A) Example
functions for the percentage of shed virus that is infectious at any time, $g_v(t)$. (B) Example application of functions
for $g_v(t)$ shown in (A) to the fitted Ct trajectory of the individual shown in Figure 5B. The worst-case scenario
reflects the original fitted Ct trajectory. (C) Corresponding estimates of the percentage of infectious shedding
remaining for the same individual and the same functions for $g_v(t)$ shown in (A). The grey vertical line indicates the
end of a four day duration-based isolation strategy. (D) Estimates of transmission potential remaining across all
symptomatic individuals following the end of a four day duration-based isolation strategy, expressed as the
number of secondary infections caused by each individual when $R_t = 1.2$.

Ct trajectories reflect the dynamics of total viral RNA in a sample rather than infectious virus (i.e., virus
with onward transmission potential). We therefore explored how estimates of shedding remaining could
be translated to estimates of infectious shedding, or transmission potential, remaining by defining three
candidate functions, $g_v(t)$, to describe the proportion of Ct-measured virus that is infectious at any given
time: (i) a worst-case scenario in which all shed virus was assumed infectious; (ii) a best-case scenario in
which all shed virus was infectious until four days post ILI symptom onset and 0% was infectious
following that time; and an intermediate scenario in which the infectiousness of shed virus decayed
linearly from 0-7 days post ILI symptom onset (Figures 6A-B) [10, 30, 37, 38]. Unsurprisingly, estimates
of infectious shedding remaining depend on the assumed infectiousness function, $g_v(t)$: for an example
individual ending isolation after four days post ILI symptom onset, the percentage of infectious virus
remaining was 0%, 5% and 17% in the best, intermediate, and worst-case scenarios, respectively (Figure
6C). Translating these estimates to the potential number of secondary infections generated per infected
individual following the end of a four-day duration-based isolation strategy (assuming $R_t = 1.2$ [49])
resulted in projections ranging from 0–0.6 across participants (Figure 6D). Given the strong assumptions
underlying each infectiousness function, these results are presented for illustration purposes only.

392
Discussion

The effectiveness of isolation strategies for individuals with symptomatic influenza virus infection
depends in part on the dynamics of virus shedding in relation to symptom timing and severity. We fit
nonlinear mixed-effects models to data from an influenza household transmission study and identified
differences in shedding by age and symptom scores by age and vaccination status. We also found
relatively low levels of pre-symptomatic, asymptomatic, and post-isolation shedding, which could have
important implications for the effectiveness of influenza control through isolation.

Young children are thought to play a central role in influenza transmission within households due to
increased susceptibility and infectivity [6, 16, 50]. Here, we found that young children aged <5 years
shed more virus than all other age groups and experienced higher peaks and longer durations of
shedding. A previous study also found children (aged ≤18 years) experienced longer durations of
shedding than adults, although there was no difference in shedding levels at symptom onset [30]. The
difference between the latter result and our identified association with peak shedding levels may be
influenced by how age groups were partitioned. The significantly higher peak shedding in children aged
<5 years found in this study would have likely been obscured if young children and adolescents (aged 5-
17 years) had been analyzed together as previously reported [30]. In addition to differences in shedding
dynamics, we identified age-related differences in symptom duration and severity. The former increased
with age and has been reported previously [7]. The latter was influenced by the chosen symptom score:
S_{ILI} scores tended to decrease with age whereas S_{ANY} and S_{UNW} scores did not. This is likely due to the
inclusion of wheezing and shortness of breath in S_{ANY} and S_{UNW}, which may offer a more sensitive
description of symptom burden in older adults for whom fever is less common.

In contrast to age, we found no difference in shedding dynamics by vaccination status. This suggests
vaccination did not reduce transmission potential in participants with breakthrough infections. Our
finding aligns with results from a previous household transmission study [37] and can help inform
mathematical modeling studies which must typically make assumptions regarding the infectiousness of
breakthrough infections in vaccinated individuals relative to unvaccinated individuals. Despite similar
shedding profiles, vaccinated infected participants did experience lower total S_{ILI} scores than their
unvaccinated counterparts. This effect was likely driven by a reduction in fever, given that the
association was present with S_{UNW} (which also includes an independent term for fever) but not with S_{ANY}
(in which wheezing or shortness of breath can compensate for the absence of fever). Our results are
consistent with a meta-analysis that found influenza-infected vaccinated individuals were significantly
less likely to develop fever than infected unvaccinated individuals, but equally likely to develop other
symptoms including cough, headache, sore throat, wheezing, fatigue, and nasal congestion [51]. More
generally, our findings highlight the importance of considering multiple scoring metrics when analyzing
individual symptom dynamics.

In addition to identifying individual differences in shedding and symptom dynamics, we explored the
potential impact of these dynamics on the effectiveness of influenza isolation measures by estimating
levels of pre-symptomatic and post-isolation shedding from symptomatic individuals, and by comparing
shedding dynamics of symptomatic individuals with those of asymptomatic individuals (who would not
be reached by isolation recommendations). We found pre-symptomatic shedding levels were relatively
low for most participants, consistent with previous work [52]. However, 15% experienced more than
50% of their shedding prior to symptom onset, suggesting isolation could miss a substantial proportion
of transmission in a small fraction of individuals. With respect to post-isolation shedding, although
longer durations of isolation will generally favor greater reductions in shedding, this effect must be

balanced with the financial and emotional burdens associated with adhering to such measures for
prolonged periods [53]. Notably, we found that isolation of all symptomatic persons for four days post
ILI symptom onset, regardless of the presence of fever, may be as effective in reducing shedding
compared with a strategy informed by current recommendations for staying at home (which had
different recommendations for people experiencing fever and would have required some participants to
isolate for six days or more). Finally, we found that asymptomatic infections were rare and shed
substantially less virus, for shorter periods of time, than symptomatic infections. Although the sample
size was small, these findings support previous analyses [13, 52] and suggest that transmission from
symptomatic individuals could comprise the majority of seasonal influenza transmission. There may also
be implications for mathematical modeling studies which often assume symptomatic and asymptomatic
infections are equally transmissible [54]. Overall, our results suggest prompt isolation of symptomatic
individuals could be an effective measure for influenza control due to generally low levels of pre-
symptomatic transmission, virus shedding post-isolation, and shedding from asymptomatic individuals.

There are several limitations to this study. First, shedding trajectories were fit to Ct values which detect
total viral RNA in a sample rather than infectious shed virus. Quantifying the latter would require
additional data, such as viral culture, that were not available for this study. Given that influenza viral
culture measures decline more rapidly than total shed virus [37], our estimates of pre-symptomatic and
post-isolation shedding are likely upper bounds on infectious virus shedding. Although these can still be
useful for planning purposes [23], modeling dynamics of infectious virus, and assessing whether these
differ by age and/or other covariates, is a critical avenue for future work. Similarly, when estimating the
number of secondary infections that occur after isolation, we assumed these were distributed in
proportion to an individual's estimated infectious shedding distribution. Although this may be largely
consistent with transmission in community settings, where isolation guidance is most applicable, it does
not account for typically higher rates of exposure and susceptible depletion that can occur within
households.

Second, we used symptom diaries to quantify symptom onset and severity, which may include reports of
symptoms caused by factors other than influenza virus infection (henceforth referred to as non-specific
symptoms). For example, individuals may be more likely to report fatigue and runny nose which have
many other causes. Reporting of non-specific symptoms may contribute to the high frequency of
symptomatic infection identified in this study compared to others [55-57]. In addition, our estimates of
pre-symptomatic shedding (which depend on the time of reported symptom onset) may be
underestimated if non-specific symptoms were reported before influenza-specific symptoms. To
mitigate these impacts, we used definitions that closely track influenza related symptoms (for example,
ILI), and excluded data from individuals who reported symptoms on three or more days with a
corresponding negative influenza test, before their first positive test. However, our symptom score
trajectories may still be biased towards earlier and/or higher values.

Finally, we used a phenomenological approach to fit the functional forms of the shedding and symptom
score data, rather than developing a mechanistic model to explain underlying virus replication and cell
infection dynamics [58-61]. This choice was motivated by data availability: fitting an appropriate and
identifiable mechanistic model for influenza virus infection requires information on viral load and
various immune cell populations that were not captured in this study. Although our approach cannot
estimate within-host parameters such as viral growth rates and infected cell lifetimes, we are still able to

capture shedding and symptoms score trajectories and explore differences in their relative timing and
magnitude.

In this work we have illustrated how phenomenological modeling of data routinely collected during
household transmission studies can elucidate virus shedding and symptom dynamics within individuals
and identify differences by age and vaccination status. Our framework can also be used to estimate the
impact of isolation in reducing influenza virus transmission, and thus inform effective strategies for
influenza isolation.

Acknowledgements: The authors would like to thank Alicia Fry, Scott Blackwell, Emma Pedigree-
Cannon, Holly Morse, Megan Eluhu, Emily Jookar, Christina Khouri, Robert Lyons, Carleigh Frazier, Janika
Raynes, Preston Gibson, Karen Malone, Sarah Davis, Olivia Doak, Judy King, and the study participants.

References

1. CDC. *Past Seasons Estimated Influenza Disease Burden*. 2023 [cited 2023 April 17]; Available
from: https://www.cdc.gov/flu/about/burden/index.html.
2. CDC, *Flu: What To Do If You Get Sick.* 2022; Available from:
https://www.cdc.gov/flu/treatment/takingcare.htm.
3. CDC. *Stay Home When You Are Sick*. 2020; Available from:
https://www.cdc.gov/flu/business/stay-home-when-sick.htm.
4. Johansson, M.A., et al., *SARS-CoV-2 Transmission From People Without COVID-19 Symptoms.*
JAMA Netw Open, 2021. **4**(1): p. e2035057.
5. Fraser, C., et al., *Factors that make an infectious disease outbreak controllable.* Proc Natl Acad
Sci U S A, 2004. **101**(16): p. 6146-51.
6. Tsang, T.K., et al., *Household Transmission of Influenza Virus.* Trends Microbiol, 2016. **24**(2): p.
123-133.
7. Petrie, J.G., et al., *Influenza transmission in a cohort of households with children: 2010-2011.*
PLoS One, 2013. **8**(9): p. e75339.
8. Xu, C., et al., *Comparative Epidemiology of Influenza B Yamagata- and Victoria-Lineage Viruses
in Households.* Am J Epidemiol, 2015. **182**(8): p. 705-13.
9. Rolfes, M.A., et al., *Household Transmission of Influenza A Viruses in 2021-2022.* JAMA, 2023.
329(6): p. 482-489.
10. Cowling, B.J., et al., *Comparative epidemiology of pandemic and seasonal influenza A in
households.* N Engl J Med, 2010. **362**(23): p. 2175-2184.
11. Levy, J.W., et al., *The serial intervals of seasonal and pandemic influenza viruses in households in
Bangkok, Thailand.* Am J Epidemiol, 2013. **177**(12): p. 1443-51.
12. Malosh, R.E., et al., *Effectiveness of Influenza Vaccines in the HIVE Household Cohort Over 8
Years: Is There Evidence of Indirect Protection?* Clin Infect Dis, 2021. **73**(7): p. 1248-1256.
13. Ip, D.K., et al., *Viral Shedding and Transmission Potential of Asymptomatic and
Paucisymptomatic Influenza Virus Infections in the Community.* Clin Infect Dis, 2017. **64**(6): p.
736-742.
14. Lau, M.S., et al., *Inferring influenza dynamics and control in households.* Proc Natl Acad Sci U S A,
2015. **112**(29): p. 9094-9.

15. Cauchemez, S., et al., *Determinants of influenza transmission in South East Asia: insights from a*
household cohort study in Vietnam. PLoS Pathog, 2014. **10**(8): p. e1004310.
16. Cauchemez, S., et al., *A Bayesian MCMC approach to study transmission of influenza: application*
to household longitudinal data. Stat Med, 2004. **23**(22): p. 3469-87.
17. Tsang, T.K., et al., *The effect of variation of individual infectiousness on SARS-CoV-2 transmission*
in households. Elife, 2023. **12**.
18. Tsang, T.K., et al., *Association between antibody titers and protection against influenza virus*
infection within households. J Infect Dis, 2014. **210**(5): p. 684-92.
19. He, X., et al., *Temporal dynamics in viral shedding and transmissibility of COVID-19.* Nat Med,
2020. **26**(5): p. 672-675.
20. Hakki, S., et al., *Onset and window of SARS-CoV-2 infectiousness and temporal correlation with*
symptom onset: a prospective, longitudinal, community cohort study. Lancet Respir Med, 2022.
10(11): p. 1061-1073.
21. WHO. *Criteria for releasing COVID-19 patients from isolation*. 2020; Available from:
https://www.who.int/news-room/commentaries/detail/criteria-for-releasing-covid-19-patients-
from-isolation.
22. Mellis, A.M., et al., *SARS-CoV-2 Virus Dynamics in Recently Infected People-Data From a*
Household Transmission Study. J Infect Dis, 2022. **226**(10): p. 1699-1703.
23. Tom, M.R. and Mina, M.J., *To Interpret the SARS-CoV-2 Test, Consider the Cycle Threshold*
Value. CID, 2020. **71**(16): p. 2252–2254.
24. Ellis, J., et al., *Evaluation of four real-time PCR assays for detection of influenza A(H1N1)v viruses*.
Euro Surveill, 2009. 14(22): p. 1-3.
25. Liao, R.S., et al., *Comparison of a laboratory-developed RT-PCR and the CDC RT-PCR protocol*
with rapid immunodiagnostic testing during the 2009 H1N1 influenza A pandemic. Diagn
Microbiol Infect Dis, 2011. **70**(2): p. 236-9.
26. Hsiao, A., et al., *Retrospective study of the use of an influenza disease two-tiered classification*
system to characterize clinical severity in US children. Hum Vaccin Immunother, 2020. **16**(8): p.
1753-1761.
27. Heikkinen, T., et al., *Clinical and socioeconomic impact of moderate-to-severe versus mild*
influenza in children. Eur J Clin Microbiol Infect Dis, 2016. **35**(7): p. 1107-13.
28. Bilcke, J., S. Coenen, and P. Beutels, *Influenza-like-illness and clinically diagnosed flu: disease*
burden, costs and quality of life for patients seeking ambulatory care or no professional care at
all. PLoS One, 2014. **9**(7): p. e102634.
29. CDC. *Flu Symptoms & Complications*. 2022 [cited 2023 8 June]; Available from:
https://www.cdc.gov/flu/symptoms/symptoms.htm.
30. Tsang, T.K., et al., *Influenza A Virus Shedding and Infectivity in Households.* J Infect Dis, 2015.
212(9): p. 1420-8.
31. Lavielle, M. and F. Mentre, *Estimation of population pharmacokinetic parameters of saquinavir*
in HIV patients with the MONOLIX software. J Pharmacokinet Pharmacodyn, 2007. **34**(2): p. 229-
49.
32. Chan, P.L., et al., *The use of the SAEM algorithm in MONOLIX software for estimation of*
population pharmacokinetic-pharmacodynamic-viral dynamics parameters of maraviroc in
asymptomatic HIV subjects. J Pharmacokinet Pharmacodyn, 2011. **38**(1): p. 41-61.
33. Shapiro, S.S. and M.B. Wilk, *An analysis of variance test for normality (complete samples).*
Biometrika, 1965. **52**(3-4): p. 591-611.
34. Burnham, K.P. and D.R. Anderson, *Multimodel Inference: Understanding AIC and BIC in Model*
Selection. Sociological Methods & Research, 2004. **33**(2): p. 261-304.

35. MacNally, R., *Regression and model-building in conservation biology, biogeography and ecology:*
The distinction between – and reconciliation of – 'predictive' and 'explanatory' models.
Biodiversity and Conservation, 2000. **9**: p. 655-671.

36. Chevan, A. and M. Sutherland, *Hierarchical partitioning.* The American Statistician, 1991. **45**: p.
90-96.

37. Suess, T., et al., *Comparison of shedding characteristics of seasonal influenza virus (sub)types*
and influenza A(H1N1)pdm09; Germany, 2007-2011. PLoS One, 2012. **7**(12): p. e51653.

38. Ip, D.K.M., et al., *The Dynamic Relationship Between Clinical Symptomatology and Viral*
Shedding in Naturally Acquired Seasonal and Pandemic Influenza Virus Infections. Clin Infect Dis,
2016. **62**(4): p. 431-437.

39. Team, R.C., *R: A Language and Environment for Statistical Computing*. 2020: R Foundation for
Statistical Computing.

40. Lavielle, M., *Rsmlx: R Speaks 'Monolix'.* R package version 5.0.1, 2022.

41. LIXOFT, *lixoftConnectors: R connectors for Lixoft Suite (@Lixoft).* R package version 2021.2, 2022.

42. Lixoft. *Monolix*. 2021; Available from: https://lixoft.com/products/monolix/.

43. Kassambara, A., *ggpubr: 'ggplot2' Based Publication Ready Plots.* R package version 0.4.0, 2020.

44. Pedersen, T.L., *patchwork: The Composer of Plots.* R package version 1.1.1, 2020.

45. Pedersen, T.L. and F. Crameri, *scico: Colour Palettes Based on the Scientific Colour-Maps.* R
package version 1.3.0, 2021.

46. Wickham, H., et al., *Welcome to the tidyverse.* Journal of Open Software, 2019. **4**(43): p. 1686.

47. Müller, K., *here: A Simpler Way to Find Your Files.* R package version 1.0.1, 2020.

48. MacNally, R. and C.J. Walsh, *Hierarchical partitioning public-domain software.* Biodiversity and
Conservation, 2004. **13**: p. 659-660.

49. Biggerstaff, M., et al., *Estimates of the reproduction number for seasonal, pandemic, and*
zoonotic influenza: a systematic review of the literature. BMC Infectious Diseases, 2014. **14**: p.
480.

50. Viboud, C., et al., *Risk factors of influenza transmission in households.* Br J Gen Pract, 2004.
54(506): p. 684-9.

51. Pan, Y., et al., *Meta-analysis of whether influenza vaccination attenuates symptom severity in*
vaccinated influenza patients. Public Health Nursing, 2022. **39**(2): p. 509-516.

52. Lau, L.L.H., et al., *Viral Shedding and Clinical Illness in Naturally Acquired Influenza Virus*
Infections. The Journal of Infectious Diseases, 2010. **201**(10): p. 1509-1516.

53. Pfefferbaum, B. and C.S. North, *Mental Health and the Covid-19 Pandemic.* New England Journal
of Medicine, 2020. **383**(6): p. 510-512.

54. Montgomery, M.P., et al., *The role of asymptomatic infections in influenza transmission: what do*
we really know. Lancet Inf Dis, 2023. DOI: 10.1016/S1473-3099(23)00619-9.

55. Leung, N.H.L., et al., *The Fraction of Influenza Virus Infections That Are Asymptomatic. A Review*
and Meta-analysis. Epidemiology, 2015. **26**(6): p. 862-872.

56. Cohen, C., et al., *Asymptomatic transmission and high community burden of seasonal influenza*
in an urban and a rural community in South Africa, 2017–18 (PHIRST): a population cohort study.
The Lancet Global Health, 2021. **9**(6): p. e863-e874.

57. Newall, A.T., et al., *Within-season influenza vaccine waning suggests potential net benefits to*
delayed vaccination in older adults in the United States. Vaccine, 2018. **36**(39): p. 5910-5915.

58. Asher, J., et al., *Novel modelling approaches to predict the role of antivirals in reducing influenza*
transmission. PLoS Comput Biol, 2023. **19**(1): p. e1010797.

59. Saenz, R.A., et al., *Dynamics of influenza virus infection and pathology.* J Virol, 2010. **84**(8): p.
3974-83.

60.   Baccam, P., et al., *Kinetics of influenza A virus infection in humans.* J Virol, 2006. **80**(15): p. 7590-
9.
61.   Dobrovolny, H.M., et al., *Assessing mathematical models of influenza infections using features of*
the immune response. PLoS One, 2013. **8**(2): p. e57088.